Abstract
Newcastle Disease Virus Vaccine (MTH-68/H) was administered to patients suffering from advanced neoplastic diseases after non-efficient tumor-destructive treatment. Case reports of selected patients suggest promising effects of this treatment. A prospectively-randomized clinical study (phase III; in accordance with Good Clinical Practice, GCP) was proposed to confirm these results and is currently under consideration.
Publication types
-
Case Reports
-
Clinical Trial
MeSH terms
-
Adult
-
Aged
-
Cancer Vaccines / therapeutic use*
-
Colorectal Neoplasms / therapy
-
Female
-
Humans
-
Immunotherapy*
-
Lung Neoplasms / secondary
-
Lung Neoplasms / therapy
-
Lymphatic Metastasis
-
Lymphoma, Non-Hodgkin / therapy
-
Male
-
Melanoma / secondary
-
Melanoma / therapy
-
Middle Aged
-
Neoplasms / therapy*
-
Newcastle disease virus / immunology*
-
Pleural Effusion, Malignant / therapy
-
Remission Induction
-
Skin Neoplasms / secondary
-
Skin Neoplasms / therapy
-
Treatment Outcome